Malignant cells elicit a chronic hemostatic activation in disease progress. This procoagulant activity does not only bear a risk for thromboembolism but also facilitates tumor growth and dissemination. An elevated plasma D-dimer level indicates an activated coagulation and fibrinolysis. In this study, the association of D-dimer levels with clinicopathological parameters and patients outcome in melanoma was investigated analyzing in total 533 melanoma patients retrospectively. Using the cut-off point of 0.6 mg/L D-dimer 145 of the total 533 patients (27.2%) were identified with elevated plasma D-dimer levels. This increased D-dimer level positively correlated with tumor thickness (p 5 0.0003), lymph node invasion (p 5 0.0004) and metastatic state (p <0.0001). To assess the association of D-dimer levels with progression-free survival (PFS) and overall survival (OS), long-rank test and the Cox proportional hazard model was performed. Univariate analyses revealed that elevated D-dimer levels were significantly associated with decreased PFS (HR:2.89, 95% CI (2.07-7.56), p < 0.0001) and OS (HR:2.22, 95% CI (1.06-4.57), p 5 0.035). Moreover, multivariate analyses identified elevated D-dimer levels being associated with poor disease outcome (PFS:HR:2.47, 95% CI (1.23-4.98), p 5 0.012; OS:HR:2.01, 95% CI (0.09-4.45), p 5 0.087). Additionally, D-dimer levels were significantly increased in terminal stage patients when comparing plasma levels 0-8 versus 24-48 weeks before death (p 5 0.0003). In summary, this study presents multiple evidence that elevated D-dimer levels in melanoma patients associate with poor prognosis and therefore plasma levels of D-dimers could reveal a more aggressive phenotype of melanoma and may guide the management of anti-melanoma treatment including the concept of an anti-coagulatory therapy in tumor patients.
Malignant melanoma is one of the most aggressive tumors, with a worse prognosis when diagnosed in the metastatic state. 1 The incidence of cutaneous melanoma is rising dramatically in the Caucasian population worldwide. 2 Standard melanoma biomarker lactate dehydrogenase (LDH) is able to predict survival of patients with distant metastases and correlates with the overall tumor load. However, it lacks prognostic accuracy for patients with loco-regional metastases. 3 The aim of this study was to investigate whether markers of hypercoagulability and fibrinolysis such as D-dimer could serve as a prognostic biomarker for melanoma patients with locally advanced or disseminated disease. Several studies have suggested an association between a more aggressive cancer phenotype and hypercoagulability, even in the absence of venous thromboembolism (VTE). [4] [5] [6] [7] Moreover, others have
shown that a hypercoagulatory state predisposes to cancer initiation. 8, 9 Case series and small cohort studies on different tumor entities indicate that tumor-related hypercoagulability is one of the most important predictive factors on overall survival (OS). However, large scale cohort studies on melanoma patients or on other single tumor entities are missing.
D-dimer, a stable end product of fibrin degradation, is a widely used and highly sensitive global indicator of activated coagulation and fibrinolysis. 10 Elevated D-dimer levels were shown in different cancer types, such as lung, colorectal, breast, ovarian cancer and pancreatic adenocarcinoma and indicate a poor prognosis in these patients. 4, [11] [12] [13] [14] [15] Moreover, it is widely known that activated coagulation is not only representing a high risk for thrombosis, but also is implicated with tumor cell invasion, angiogenesis and metastatic spread. [16] [17] [18] [19] [20] In this context, our own studies demonstrated that highly invasive melanoma cells are able to activate the vascular endothelium resulting in a release of coagulation and angiogenesis-associated factors [von Willebrand factor (VWF), P-selectin, Angiopoietin-2 (Ang-2)], that are known to promote tumor progression. [21] [22] [23] [24] Recently, we could also provide evidence for elevated VWF plasma concentrations and VWF fibers in tumor blood vessels of melanoma patients, 25 indicating a tumor-cell-mediated activation of coagulation. In order to address the problem of activated coagulation in cancer patients several studies have focused on the effect of heparin on tumor progression. 26, 27 Recent clinical studies have demonstrated an inhibitory effect of low molecular weight heparins (LMWH) on tumor growth and metastasis, resulting in a beneficial effect on the survival of cancer patients. [28] [29] [30] Our study was based on the hypothesis that tumor activity is displayed by elevated D-dimer plasma levels and that Ddimers might be used as a prognostic marker in patients with metastatic malignant melanoma. Our aim for this study was also to provide a novel insight in the dynamic variation of D-dimer levels in malignant melanoma patients. In summary, our data confirm the impact and relevance of tumormediated hypercoagulability on patients' outcome. We show for the first time that D-dimer levels correlate with tumor thickness and tumor progression. What is more elevated Ddimer levels correlate significantly with progression-free survival (PFS) and OS. The D-dimer levels demonstrated the strongest effect on OS, compared to metastatic stage, LDH and S100B.
Material and Methods

Study patients
This study included 533 patients with histologically proven malignant melanoma (AJCC 2009 stages I-IV) that were treated at the Skin Cancer Center, University Medical Center Mannheim, Germany. A retrospective 5-year follow-up was performed to study PFS and a 2-year retrospective follow-up for the analyses of OS. Follow-up time was defined from the date of diagnosis of stage III (for PFS) or diagnosis of stage IV (for OS) to the date of last follow-up, disease progression (for PFS) or disease-specific death (for OS). Samples were selected according to the following criteria: histologically confirmed malignant melanoma, complete documentation of medical history, course of the disease, and follow-up. Detailed patients characteristics are presented in Table 1 . Patients with pre-existing comorbidities or medications affecting D-dimer values (including venous or arterial thromboembolism in the preceding 6 months or intake of continuous anticoagulants, cardiovascular disease, acute or chronic inflammatory disease or history of a second primary tumor) were excluded from the study. All included patients were above 18 years of age. The collection of plasma and documentation of clinical data were performed after patients' informed consent with institutional review board approval. Disease staging was done according to the criteria of the AJCC. 31 
Statistical analyses
Continuous data are presented as the median and the interquartile range (IQR; range from the 25th to the 75th percentile), or as mean 6 SEM (standard error of mean). Differences between multiple groups were analyzed using the KruskalWallis test and between two groups using the two-sided Student's t test or the Mann-Whitney U test. PFS was analyzed from the date of diagnosis of stage III to the date until disease progressed in a time interval of 5 years. Survival time was calculated from the date of diagnosis of stage IV to the date of death from the disease or the last control in a time interval of 2 years. Survival curves were constructed using the KaplanMeier method and compared using the long-rank (MantelCox) test. Results of the Cox models are presented as the hazard ratio (HR) and the 95% confident intervals (95% CI). Both univariate and multivariate survival analyses were performed 
Results
In total, 533 melanoma patients (stages I-IV) were retrospectively included in this study. Their detailed demographic and clinical characteristics are listed in Figure 1 ). Multivariate analyses, using the Cox proportional hazard model, revealed that besides the expected Tumor stage (p 5 0.007) and Node stage (p < 0.0001) plasma D-dimer levels (p 5 0.012) were significant independent prognostic markers of PFS in malignant melanoma stage III patients (Table 2) .
Plasma D-dimer levels and OS of stage IV melanoma patients
In total, 81 stage IV melanoma patients were analyzed for OS according to their D-dimer levels. The cut-off value for plasma D-dimer was defined at 0.6 mg/L, based on the ROC curve analysis ( Figure S4 , Supporting Information). The sensitivity and specificity for prediction of metastasis were 49% and 75%, respectively. For the analysis of the prognostic value of normal versus elevated D-dimer levels, stage IV melanoma patients were divided in two groups according to their D-dimer levels (D-dimer levels 0.6 mg/L versus D-dimer levels <0.6 mg/L). Elevated D-dimer levels were significantly associated with poor OS (log-rank test: p 5 0.035). The probabilities of OS between the two groups were 89% (D-dimer levels <0.6 mg/L) and 69% (D-dimer levels 0.6 mg/L) after 1 year and further declined to 74% (D-dimer levels <0.6 mg/ L) and 54% (D-dimer levels 0.6 mg/L) after 2 years ( Figure  2 ). Based on the log-rank proportional hazards regression (HR) analyses, OS was significantly influenced by D-dimer levels (HR: 2.22, 95% CI: 1.06-4.57, p 5 0.035) and S100B (HR: 2.15, 95% CI: 1.02-4.56, p 5 0.045) ( Table 3) . A multivariate analysis using the Cox proportional hazard model showed that in our study the metastatic stage (p 5 0.512), LDH (p 5 0.667) and S100B (p 5 0.289) had no significant effect on OS. However, D-dimer levels showed the strongest effect on OS (p 5 0.087), when compared to the other factors but failed to demonstrate independence (Table 3 ). In order 
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to rule out the possibility that D-dimer levels were increased due to an acute-phase reaction, a correlation of D-dimer levels with corresponding levels of C-reactive Protein (CRP) was performed and excluded a significant correlation (r 5 0.144, p 5 0.102).
Dynamic variation of D-dimers in disease progress
To analyze the dynamic variation of D-dimer levels in disease progress, D-dimer levels of patients 24-48 weeks versus 0-8 weeks before death were compared. Here, D-dimers showed a gradual increase from 24-48 weeks to 0-8 weeks before patient s death with a statistically significant difference between the two time intervals (median D-dimer level 24-48 weeks: 0.71 mg/L; 0-8 weeks: 2.4 mg/L, p 5 0.0003; Figure  3A ). An example for D-dimer levels over the clinical course is given in Figure 3B .
Discussion
Activated coagulation in cancer patients is implicated both in tumor progression and in development of VTE. 16, 17, 20 While several studies have linked activated coagulation with many different cancer types, 32 there are only few publications in malignant melanoma. 33, 34 To our knowledge, this is the first large-scale cohort study examining the association between coagulation and survival in malignant melanoma patients. In this study, we demonstrated that D-dimers were significantly increased in patients with metastatic disease, especially in the case of visceral metastases, such as liver but also brain or bone (stage M1c), compared to melanoma patients without metastases ( Figure S1A , Supporting Information). In line with our results, Bottasso et al. showed in 71 melanoma patients [45 with localized tumors (stage IA and IB) and 25 with metastases (stages II-IV)] that plasma D-dimer levels were elevated in melanoma patients compared to healthy controls with benign nevi and D-dimer levels were significantly higher in metastatic melanoma. 33 In contrast to this work another study published by Tas et al. including 61 melanoma patients [stage I-II (n 5 10), stage III (n 5 14), stage IV (n 5 37)] showed higher D-dimer levels in the melanoma group compared to control patients, but they could not find a correlation to the metastatic stage and see no significant effect on survival (1-year follow-up). 34 Both studies fall short in size and variation of the study population, as the study from Bottasso et al. 33 have significantly more patients in the early stage of melanoma (stage I and II), the study of Tas et al. 34 included more patients in the advanced stage (stage III and IV) of the disease. Here, we present data from the largest cohort of patients published so far that is equally distributed over all melanoma stages from IA to M1c and the follow-up time were 5-years for PFS and 2-years for OS analyses. Furthermore, a significant difference was observed between histological subtypes of melanoma, at which the highest D-dimer levels were observed in Acral lentiginous melanoma (ALM) and the lowest levels in superficial spreading melanoma (SSM) ( Figure S1B , Supporting Information). In this context its known that despite the rarity of ALM, accounting for only about 2-3% of all melanomas, 35 ALM is thought to carry a worse prognosis when compared to other melanoma histotypes. 36 Moreover, a positive correlation of D-dimers was found with tumor thickness, lymph node invasion and metastatic state. A retrospective study of Luen et al. showed that the primary tumor thickness is a significant prognostic factor in stage IV melanoma, here patients with primary tumors of <2 mm had an improved median survival of 2.4 months compared to those patients with primary tumor thickness 2 mm. 37 In this context, our results show also significant higher D-dimer levels in patients with primary tumor thickness 2 mm compared to patients with primary tumors of <2 mm ( Figure S1C, Supporting Information) . In correlation to our results, showing that D-dimer levels increase with the amount of positive lymph nodes ( Figure  S1D , Supporting Information), a number of studies have demonstrated that lymphatic invasion in primary melanoma is associated with a positive sentinel lymph node biopsy and a worse clinical outcome. [38] [39] [40] In addition to the observation that D-dimers are significantly increased in stage M1c patients, compared to them in stage M1a and M1b ( Figure  S1E , Supporting Information), we also found that D-dimers are significantly increased when liver or bone metastases are present (Table S3 , Supporting Information). Here it is known that the site of distant metastases is an important independent prognostic marker for OS in patients with metastatic disease. 41 In this context, the 2009 AJCC melanoma database analysis, reveal that patients with loco-regional, distant nodal and soft tissue metastases have a better survival than the patients with visceral metastases. 31 Further patients in whom the lung was the only site of metastases had a better 1-year survival duration time compared with those with metastases in other visceral organs. Interestingly, our results showed that in comparison to other metastatic sites the lowest median levels of D-dimers were observed in patients with lung metastases (Table S3 , Supporting Information). 
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The prognosis of patients with metastatic melanoma is poor despite novel treatment approaches that have improved OS recently. In our study, patients with elevated D-dimer levels show significant reduced PFS and OS (Figures 1 and 2) . High levels of D-dimers have been associated with worse prognosis in several cancer types, including lung, colorectal, breast, ovarian cancer and pancreatic adenocarcinoma. 4, [11] [12] [13] [14] [15] Recently, Go et al. 42 demonstrated that elevated D-dimer levels in metastatic gastric cancer patients are associated with significantly shorter OS and suggested to use D-dimer as a prognostic and predictive biomarker for response to chemotherapy and OS in these patients. In our study, univariate analysis on OS showed that high levels of D-dimer and S100B were significantly associated with an adverse outcome and a higher risk of death. Using the cut-off level of 0.6 mg/ L, multivariate analysis using the Cox regression model revealed the significance of higher levels of D-dimer for OS of metastatic melanoma patients. The D-dimer levels demonstrated the strongest effect on OS, compared to Metastatic stage, LDH and S100B. Those patients with D-dimer levels 0.6 mg/L were 2.01-fold more likely to die than the patients with D-dimer levels below this cut-off value. Additionally in a 5-year retrospective follow-up 100 stage III melanoma patients were analyzed on PFS according to their D-dimer level. Here we could show, that tumor thickness, lymph node invasion and an elevated D-dimer level significantly correlates with reduced PFS (Figure 1 , Table 2 ).
In this study, we also reviewed the dynamic variation of D-dimers in 15 terminal stage patients. Here we compare the D-dimer levels in the 0-8 week's period with the 24-48 weeks period before patient's death. Interestingly, here we could find a strong significant difference of D-dimer levels between the two time periods. D-dimers increase when patients were close to death ( Figure 3A In some clinical trials, anticoagulation drugs have been reported to be effective in the prevention and treatment of hematogenous metastases, and in the prolongation of survival. [43] [44] [45] [46] Besides the antithrombotic impact of LMWHs, 27, 47 accumulating clinical evidence suggests that LMWH significantly improve disease progression and OS directly by its antitumor effect. Indeed, in vitro and in vivo studies also from our group have shown that LMWHs could influence angiogenesis, cancer cell adhesion, tumor cell proliferation, local tumor growth and metastases through a number of coagulation-independent mechanisms. 25, 30, [48] [49] [50] However, there are some limitations concerning this study, such as the retrospective design and the missing investigation on the influence of anti-cancer treatment on progression and survival. Another limitation of this study is that we only ruled out symptomatic VTE events during the follow-up period, so asymptomatic VTE cannot be excluded.
In conclusion, our results provide evidence for the hypothesis that elevated D-dimer levels in melanoma patients with advanced disease indicate a poor prognosis, and we demonstrate that measurement of D-dimers could identify patients with a more aggressive clinical course of metastatic melanoma and may guide treatment decisions in the clinical management of disease. Moreover, our data envisions that an additionally anticoagulatory therapy may not only prevent VTE but improve patients outcome, though further studies are needed.
